For almost a year, we’ve featured the authors of our monthly Cerebrum articles in a Q & A. With the May Cerebrum article, “A New Approach for Epilepsy,” we are transitioning to a podcast.
Why are we taking this new approach? We suspect that visitors to the website, with already quite a bit to read, will welcome an audio option. We also think it will be valuable to hear some of the top researchers in the field offer their opinions and explain some of the complex biological, neurochemical, or genetic advances that they write about in Cerebrum, the Dana Foundation’s research-based publication.
Our first guests are Ray Dingledine, Ph.D., and Bjørnar Hassel, M.D., Ph.D.—longtime research collaborators who met by chance in Norway. Dingledine is professor and chair of the Department of Pharmacology at Emory University School of Medicine in Atlanta, serves on the scientific advisory board of the Epilepsy Project, and chairs the investment committee for the Society for Neuroscience. Hassel, a neurologist and a biochemist, is professor and senior consultant at the University of Oslo, Department of Neurohabilitation.
Their article focuses on a new study from a research group that may very well initiate a shift to new therapeutic approaches for one-third of the 65 million people worldwide affected by epilepsy and who are treatment-resistant. But they also provide an overview of the disorder, the evolution of drug development, and discuss the pros and cons of a high-fat diet that is capable of alleviating symptoms in young children.
Thoughtful and eloquent, we couldn’t have picked better guests to launch our new podcast. We hope you enjoy this new feature and welcome any and all feedback.
– Bill Glovin